Result of AGM

Cambridge Antibody Tech Group PLC
1 February 2002

2/CAT/05

Page 1 of 2

FOR IMMEDIATE RELEASE

13.30 GMT 08.30 EST Friday 1 February 2002


For Further Information Contact:
Cambridge Antibody Technology                          Weber Shandwick Square Mile (Europe)
Tel: [phone]                              Tel: [phone]
David Chiswell, Chief Executive Officer                Kevin Smith
John Aston, Finance Director                           Graham Herring
Rowena Gardner, Head of Corporate Communications
                                                       BMC Communications/The Trout Group (USA)
                                                       Tel: [phone]
                                                       Brad Miles, ext. 17 (media)
                                                       Brandon Lewis, ext. 15 (investors)


CAMBRIDGE ANTIBODY TECHNOLOGY REPORTS OUTCOME OF ANNUAL GENERAL MEETING

Melbourn, UK... Cambridge Antibody Technology (LSE: CAT, NASDAQ: CATG) reports
that at its Annual General Meeting, held at 1.00pm on Friday 1 February 2002,
all resolutions were duly passed.

                                     -ENDS-


Notes to Editors:

Cambridge Antibody Technology (CAT)

•         CAT is a UK biotechnology company using its proprietary technologies
in human monoclonal antibodies for drug discovery and drug development.  Based
near Cambridge, England, CAT currently employs around 260 people.

•         CAT is listed on the London Stock Exchange and on NASDAQ since June
2001. CAT raised £41m in its IPO in March 1997 and £93m in a secondary offering
in March 2000.

•         CAT has an advanced platform technology for rapidly isolating human
monoclonal antibodies using phage display systems. CAT has extensive phage
antibody libraries, currently incorporating more than

•         100 billion distinct antibodies. These libraries form the basis for
the Company's strategy to develop a portfolio of antibody-based drugs and to
utilise antibodies as tools for target validation.  Six human therapeutic
antibodies developed by CAT are at various stages of clinical trials.

•         CAT has alliances with a large number of biotechnology and
pharmaceutical companies to discover, develop and commercialise human monoclonal
antibody-based products. CAT has also licensed its proprietary human antibody
phage display libraries to several companies for target validation and drug
discovery. CAT's collaborators include: Abbott, AMRAD, Elan, Eli Lilly, Genetics
Institute, Genzyme, Human Genome Sciences, Immunex, Incyte, Merck & Co., Inc,
Oxford GlycoSciences, Pharmacia, Pfizer, Wyeth-Ayerst, Xerion and Zyomyx.

Application of the Safe Harbor of the Private Securities Litigation Reform Act
of 1995: This press release contains statements about CAT that are forward
looking statements.  All statements other than statements of historical facts
included in this press release may be forward looking statements within the
meaning of Section 21E of the US Securities Exchange Act of 1934.

These forward looking statements are based on numerous assumptions regarding
CAT's present and future business strategies and the environment in which CAT
will operate in the future.  Certain factors that could cause CAT's actual
results, performance or achievements to differ materially from those in the
forward looking statements include: market conditions, CAT's ability to enter
into and maintain collaborative arrangements, success of product candidates in
clinical trials, regulatory developments and competition.


                      This information is provided by RNS
            The company news service from the London Stock Exchange